Combination of tadalafil and finasteride for improving the symptoms of benign prostatic hyperplasia: critical appraisal and patient focus

Item

http://www.wikidata.org/entity/Q27008847

description

2015 nî lūn-bûn

@nan

2015 թուականին հրատարակուած գիտական յօդուած

@hyw

2015 թվականին հրատարակված գիտական հոդված

@hy

2015年の論文

@ja

2015年論文

@yue

2015年論文

@zh-hant

2015年論文

@zh-hk

2015年論文

@zh-mo

2015年論文

@zh-tw

2015年论文

@wuu

name

Combination of tadalafil and f ...... al appraisal and patient focus

@ast

Combination of tadalafil and f ...... al appraisal and patient focus

@en

Combination of tadalafil and f ...... al appraisal and patient focus

@nl

type

Item

label

Combination of tadalafil and f ...... al appraisal and patient focus

@ast

Combination of tadalafil and f ...... al appraisal and patient focus

@en

Combination of tadalafil and f ...... al appraisal and patient focus

@nl

prefLabel

Combination of tadalafil and f ...... al appraisal and patient focus

@ast

Combination of tadalafil and f ...... al appraisal and patient focus

@en

Combination of tadalafil and f ...... al appraisal and patient focus

@nl

P1476

Combination of tadalafil and f ...... al appraisal and patient focus

@en

P2093

Edward Kim

http://www.w3.org/2001/XMLSchema#string

Osama Elkelany

http://www.w3.org/2001/XMLSchema#string

Ryan Owen

http://www.w3.org/2001/XMLSchema#string

P2860

Tamsulosin, the first prostate-selective alpha 1A-adrenoceptor antagonist. A meta-analysis of two randomized, placebo-controlled, multicentre studies in patients with benign prostatic obstruction (symptomatic BPH). European Tamsulosin Study Group.

Incidence and prevalence of lower urinary tract symptoms suggestive of benign prostatic hyperplasia in primary care--the Triumph project.

Efficacy and safety of a dual inhibitor of 5-alpha-reductase types 1 and 2 (dutasteride) in men with benign prostatic hyperplasia.

Efficacy and safety of tadalafil once daily in the treatment of men with lower urinary tract symptoms suggestive of benign prostatic hyperplasia: results of an international randomized, double-blind, placebo-controlled trial.

EAU guidelines on the treatment and follow-up of non-neurogenic male lower urinary tract symptoms including benign prostatic obstruction.

The effect of finasteride on the risk of acute urinary retention and the need for surgical treatment among men with benign prostatic hyperplasia. Finasteride Long-Term Efficacy and Safety Study Group.

Tadalafil for the treatment of lower urinary tract symptoms secondary to benign prostatic hyperplasia: pathophysiology and mechanism(s) of action.

Critical analysis of the relationship between sexual dysfunctions and lower urinary tract symptoms due to benign prostatic hyperplasia.

The mechanism of action of phosphodiesterase type 5 inhibitors in the treatment of lower urinary tract symptoms related to benign prostatic hyperplasia.

The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.

P304

507-13

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.2147/TCRM.S80353

http://www.w3.org/2001/XMLSchema#string

P407

English

P478

http://www.w3.org/2001/XMLSchema#string

P577

2015-01-01T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

25848297

http://www.w3.org/2001/XMLSchema#string

P932

4386768

http://www.w3.org/2001/XMLSchema#string